Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previous
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... HILL, Conn. , July 29, 2014 Numotion,s ... 2014, Mike Swinford will be the company,s new ... a highly successful 22-year career at GE where he worked ... million in annual revenue to over $5 billion. His most ... Global Services. "I am thrilled to join ...
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education ... for the science, technical, and medical communities, has announced ... first off-line mobile application of the world-renowned medical education ... new AccessMedicine App , available for download onto ... now be able to gain access to valuable ...
(Date:7/29/2014)... 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... its second quarter 2014 financial results after the Nasdaq ... then host a live conference call and webcast to ... Thursday morning, August 7, 2014 at 8:00 a.m. Eastern ... access the live conference call by dialing 866-952-1907 (US) ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... China, Dec. 16, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical ... the "Company"), a developer, manufacturer and distributor of botanical ... that Mr. David Dong was named the Company,s new ... Mr. Dong,s career spans over 10 years ...
... Dec. 16, 2010 WaferGen Biosystems, Inc. (OTC Bulletin ... state-of-the-art genomic analysis systems, and the Integrated BioBank of ... strategic relationship that will expand the use of the ... personalized medicine.   The agreement includes: ...
Cached Medicine Technology:China Botanic Appoints David Dong as New Chief Financial Officer 2China Botanic Appoints David Dong as New Chief Financial Officer 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 2WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 3WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 4WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System 5
(Date:7/29/2014)... News) -- Decorative contact lenses may seem like a ... cause serious eye damage. Decorative contacts should be ... the U.S. Food and Drug Administration (FDA). It,s important ... for these lenses and buy them from a trustworthy ... about the potential health risks associated with decorative contact ...
(Date:7/29/2014)... 29, 2014 July 29, 2014 – Silverado, ... is proud to announce that it is a Bronze winner ... video segments; Silverado Through a Child's Eye and ... In Silverado Through a Child's Eye , seven-year-old Mia ... at Silverado Beverly Place, a memory care community in Los ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 According ... marijuana in both the recreational and the medicinal sectors ... As legalized marijuana becomes more accepted in mainstream culture, ... drug aside from the traditional and more dangerous forms ... products are becoming quite the trend in legalized states ...
(Date:7/29/2014)... Boca Raton, FL (PRWEB) July 29, 2014 ... will officially launch its products in the UK in September. ... company’s products will be available Sept. 7 on Amazon.co.uk. , ... has been growing and we are truly looking forward to ... Amazon.co.uk will include OZ Naturals bestselling Vitamin C serum ...
(Date:7/29/2014)... July 29, 2014 PhyMed Healthcare ... anesthesia, pain management and critical care, has named Ryan ... to PhyMed in May 2013 as our vice president ... part of our organization and leadership team,” says Dr. ... is a cornerstone of our strategic vision and Ryan ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Marijuana Edibles Sales Show Growth in Market 2Health News:OZ Naturals to Launch Its Products in the UK 2Health News:PhyMed Names Dorr to Chief Information Office Post 2
... Tata Industries Ltd today said it has acquired a ... indigene Pharma Inc// , for an undisclosed amount. ... in the business of both prescription and consumer healthcare ... Indigene, Tata Group Chairman Ratan Tata said the group ...
... at rest the "controversy" over the number of HIV/AIDS patients ... its figures of 5.2 million// patients was in consonance with ... figures on HIV/AIDS patients are for the age group of ... prone to the disease," Sujata Rao, Director-General, NACO told reporters ...
... in Malaysia Putrajaya Malaysia, The Malaysian government proposes ... HIV/AIDS// sufferers who falsify information about their condition to ... Infectious Diseases Act 1988 would be amended to make ... Razak said. ,"There have been several cases ...
... Health Department in June, officials had pointed out certain ... had revealed certain lapses in the candy production area, ... entry points for rodents. Despite necessitating immediate remedies by ... had done precious little to correct the irregularities., ...
... innovation to examine one’s heart.Usually an angiogram is performed where ... the groin or forearm and advanced through the arterial system ... This would take a few hours but for a patient ... to six hours. But this new 64-slice CT scanner which ...
... receives cochlear implants better will be his or her spoken language ... 3? year-old child, born as deaf but used cochlear implants, able ... make use of it. ,In contrast, a child of ... made more sophisticated statements: ‘OK, now the people goes to stand ...
Cached Medicine News:Health News:Earlier the Cochlear Implants Used Better the Speech 2Health News:Earlier the Cochlear Implants Used Better the Speech 3
... eyewear and sunwear, inspired by ... personal style, with long lasting ... the collection include sophistication, elegance ... offer clean modern shapes, classic ...
... designs with children in mind, making eyewear ... stay-put cable temples. Its not surprising that ... as the best selling childrens collection from ... popular is its ability to keep pace ...
... The Calvin Klein Collection. Provocatively inspired ... - a bold outlook. Innovative structure: ... Modern technology enhances modern design. Technological ... and enhance the face., ,The Calvin ...
Inquire...
Medicine Products: